Enhanced immunogenicity and cross-reactivity of HIV-1 V3-peptide and multiple antigen peptides conjugated to distinct carrier proteins

Cruz, Luis J.; Cabrales, Ania; Iglesias, Enrique V.; Aguilar, Julio César; González, Luis Javier; Reyes, Osvaldo

doi:10.1016/j.intimp.2009.08.026

Cited by 8 publications

(7 citation statements)

References 45 publications

(50 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Synthetic peptides corresponding to Bcell epitopes have shown promise as vaccines for combating pathogenic infections. Recently, synthetic peptide vaccines have been tested against coronavirus (He et al, 2006), human immunodeficiency virus 1 (Cruz et al, 2009), influenza A virus (Wang et al, 2010), Toxoplasma gondii (Tan et al, 2010), and Yersinia pestis (Tripathi et al, 2006;Khan et al, 2008). Therefore, to determine the B-cell epitope of EV70 is an important step in developing a peptide vaccine for EV70.…”

Section: Introductionmentioning

confidence: 99%

A peptide vaccine based on a B-cell epitope on the VP1 protein of enterovirus 70 induces a strong antibody response

Park¹,

Lim²,

Ye³

et al. 2012

View full text Add to dashboard Cite

Summary. -Enterovirus 70 (EV70) is the causative agent of acute hemorrhagic conjunctivitis (AHC), for which no effective vaccine is available. This study revealed a high reactivity of the N-terminal region of EV70 VP1 (VP1-1) with an anti-EV70 mouse serum. The analysis of overlapping synthetic peptides of VP1-1 identified a B-cell epitope in this region. The E-peptide (14-ANTVESEIKAELGVI-28) showing the highest reactivity with the anti-EV70 serum induced neutralizing antibodies in mice and reduced the virus titer in the eyes, suggesting that it is a candidate vaccine against AHC caused by EV70.Keywords: enterovirus 70; AHC; B-cell epitope; peptide vaccine * Corresponding author. E-mail: jhnam@catholic.ac.kr; phone: +82-2-2164-4917. # These authors contributed equally to this work. Abbreviations: EV70 = enterovirus 70; AHC = acute hemorrhagic conjunctivitis; VP1-1 = virus capsid protein VP1 amino-terminus; VP1-2 = virus capsid protein VP1 middle; VP1-3 = virus capsid protein carboxy-terminus

show abstract

Section: Introductionmentioning

confidence: 99%

A peptide vaccine based on a B-cell epitope on the VP1 protein of enterovirus 70 induces a strong antibody response

Park¹,

Lim²,

Ye³

et al. 2012

View full text Add to dashboard Cite

show abstract

“…The carrier protein is another important factor that affects the immune effects of immunogens (35). The differences in antisera affinity between hapten 1-KLH and hapten 1-BSA may be due to distinct immunogenicities and hapten-carrying capabilities of the carrier proteins.…”

Section: Discussionmentioning

confidence: 99%

Development of an enzyme‑linked immunosorbent assay for camptothecin

et al. 2019

View full text Add to dashboard Cite

The use of camptothecin and its analogues has increased in clinical settings and in agriculture. Therefore, camptothecins and their derivatives, metabolites and degradation products are frequently found in the environment. Therefore, it is important to develop an ELISA for the quantification of camptothecins in human plasma, plants, animal tissues and other matrices. The present study developed a novel competitive indirect ELISA for camptothecin using a monoclonal antibody (MAb). In total, two haptens and various carrier proteins were tested to select the most suitable immunogen for the production of MAbs against camptothecin. Hapten 1 conjugated with keyhole limpet hemocyanin was selected for the preparation of MAb 5A3, and was used to establish a competitive indirect ELISA for camptothecin. A total of three derivatives of camptothecin used in clinical practice were examined. Topotecan showed an IC 50 value of 0.68 µg/ml with a detection limit of 0.19 µg/ml, belotecan showed an IC 50 value of 0.87 µg/ml with a detection limit of 0.22 µg/ml and irinotecan showed an IC 50 value of 2.85 µg/ml with a detection limit of 0.47 µg/ml. The cross-reactivity results suggested that the assay developed in the present study possessed a high sensitivity to camptothecin. Therefore, this immunoassay technique may be suitable for monitoring the levels of camptothecin in compound analysis, clinical applications, and analyses of food and environmental samples.

show abstract

“…Furthermore, these carriers offer more sites for the coupling of synthetic peptides. By contrast, carrier-MAP conjugates are more immunogenic than carrier-peptides [42].…”

Section: Direct Antigen Vaccination Using a Series Of Presentation Stmentioning

confidence: 93%

Enhancing Immunogenicity and Cross-Reactivity of HIV-1 Antigens by In Vivo Targeting to Dendritic Cells

et al. 2012

View full text Add to dashboard Cite

Current retroviral treatments have reduced AIDS to a chronic disease for most patients. However, given drug-related side effects, the emergence of drug-resistant strains and the persistence of viral replication, the development of alternative treatments is a pressing need. This review focuses on recent developments in HIV immunotherapy treatments, with particular emphasis on current vaccination strategies for optimizing the induction of an effective immune response by the recruitment of dendritic cells. In addition to cell-based therapies, targeted strategies aiming to deliver synthetic HIV peptides to dendritic cell-specific receptors in vivo will be discussed.

show abstract

Enhanced immunogenicity and cross-reactivity of HIV-1 V3-peptide and multiple antigen peptides conjugated to distinct carrier proteins

Cited by 8 publications

References 45 publications

A peptide vaccine based on a B-cell epitope on the VP1 protein of enterovirus 70 induces a strong antibody response

A peptide vaccine based on a B-cell epitope on the VP1 protein of enterovirus 70 induces a strong antibody response

Development of an enzyme‑linked immunosorbent assay for camptothecin

Enhancing Immunogenicity and Cross-Reactivity of HIV-1 Antigens by In Vivo Targeting to Dendritic Cells

Contact Info

Product

Resources

About